Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin E2 signaling: Recent advances in basic biology

Yong I. Cha, Raymond N. DuBois

Research output: Contribution to journalArticle

Abstract

Experimental evidence collected over the past decade has revealed that targeting cyclooxygenase-2 (COX-2) may have some efficacy for chemoprevention of cancer. However, recent safety concerns over the long-term use of COX-2 selective inhibitors are prompting research aimed at identifying other specific targets downstream of COX-2. In this regard, several groups have found that NSAIDs and COX-2 selective inhibitors primarily reduce the production of prostaglandin (PG) E2, a biologically active lipid product of the COX-2 enzyme, which results in attenuation of PGE2 signaling in the tumor microenvironment. Therefore, a detailed understanding of the PGE 2 signaling pathway in transformed cells is critical to help identify novel and safer targets for effective prevention and/or treatment of cancer. Here we review the recent advances in elucidating the molecular mechanisms by which PGE2 promotes carcinogenesis.

Original languageEnglish (US)
Pages (from-to)60-65
Number of pages6
JournalCurrent Colorectal Cancer Reports
Volume2
Issue number2
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Chemoprevention
Cyclooxygenase 2
Dinoprostone
Colorectal Neoplasms
Cyclooxygenase 2 Inhibitors
Tumor Microenvironment
Non-Steroidal Anti-Inflammatory Agents
Prostaglandins E
Neoplasms
Carcinogenesis
Lipids
Safety
Enzymes
Research
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin E2 signaling : Recent advances in basic biology. / Cha, Yong I.; DuBois, Raymond N.

In: Current Colorectal Cancer Reports, Vol. 2, No. 2, 03.2006, p. 60-65.

Research output: Contribution to journalArticle

@article{ae4529b7eb8941cca1b7afbbc44f76d1,
title = "Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin E2 signaling: Recent advances in basic biology",
abstract = "Experimental evidence collected over the past decade has revealed that targeting cyclooxygenase-2 (COX-2) may have some efficacy for chemoprevention of cancer. However, recent safety concerns over the long-term use of COX-2 selective inhibitors are prompting research aimed at identifying other specific targets downstream of COX-2. In this regard, several groups have found that NSAIDs and COX-2 selective inhibitors primarily reduce the production of prostaglandin (PG) E2, a biologically active lipid product of the COX-2 enzyme, which results in attenuation of PGE2 signaling in the tumor microenvironment. Therefore, a detailed understanding of the PGE 2 signaling pathway in transformed cells is critical to help identify novel and safer targets for effective prevention and/or treatment of cancer. Here we review the recent advances in elucidating the molecular mechanisms by which PGE2 promotes carcinogenesis.",
author = "Cha, {Yong I.} and DuBois, {Raymond N.}",
year = "2006",
month = "3",
doi = "10.1007/s11888-006-0003-1",
language = "English (US)",
volume = "2",
pages = "60--65",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin E2 signaling

T2 - Recent advances in basic biology

AU - Cha, Yong I.

AU - DuBois, Raymond N.

PY - 2006/3

Y1 - 2006/3

N2 - Experimental evidence collected over the past decade has revealed that targeting cyclooxygenase-2 (COX-2) may have some efficacy for chemoprevention of cancer. However, recent safety concerns over the long-term use of COX-2 selective inhibitors are prompting research aimed at identifying other specific targets downstream of COX-2. In this regard, several groups have found that NSAIDs and COX-2 selective inhibitors primarily reduce the production of prostaglandin (PG) E2, a biologically active lipid product of the COX-2 enzyme, which results in attenuation of PGE2 signaling in the tumor microenvironment. Therefore, a detailed understanding of the PGE 2 signaling pathway in transformed cells is critical to help identify novel and safer targets for effective prevention and/or treatment of cancer. Here we review the recent advances in elucidating the molecular mechanisms by which PGE2 promotes carcinogenesis.

AB - Experimental evidence collected over the past decade has revealed that targeting cyclooxygenase-2 (COX-2) may have some efficacy for chemoprevention of cancer. However, recent safety concerns over the long-term use of COX-2 selective inhibitors are prompting research aimed at identifying other specific targets downstream of COX-2. In this regard, several groups have found that NSAIDs and COX-2 selective inhibitors primarily reduce the production of prostaglandin (PG) E2, a biologically active lipid product of the COX-2 enzyme, which results in attenuation of PGE2 signaling in the tumor microenvironment. Therefore, a detailed understanding of the PGE 2 signaling pathway in transformed cells is critical to help identify novel and safer targets for effective prevention and/or treatment of cancer. Here we review the recent advances in elucidating the molecular mechanisms by which PGE2 promotes carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84873384269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873384269&partnerID=8YFLogxK

U2 - 10.1007/s11888-006-0003-1

DO - 10.1007/s11888-006-0003-1

M3 - Article

AN - SCOPUS:84873384269

VL - 2

SP - 60

EP - 65

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 2

ER -